Atopic Dermatitis in SOC

CE / CME

Addressing the Disproportionate Burden of Moderate to Severe Atopic Dermatitis in Patients With Skin of Color: Expert Perspectives for NPs and PAs

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: January 15, 2025

Expiration: January 14, 2026

Victoria Garcia-Albea
Victoria Garcia-Albea, PNP, DCNP

Activity

Progress
1 2
Course Completed

Introduction

In this module, Victoria Garcia-Albea, PNP, DCNP highlights the disproportionate racial burden of atopic dermatitis (AD) and shares strategies to improve outcomes in patients with moderate to severe AD.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Practicing Clinicians Exchange plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared. 

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with AD do you provide care for in a typical week?

When assessing AD severity in patients with skin of color, what surrogate measure can be used as an adjunctive assessment?

You would like to initiate dupilumab in a Black patient with uncontrolled moderate AD, but the patient is nervous about this switch. You share that subgroup analysis of clinical trials has revealed which of the following outcomes regarding efficacy and safety in patients with skin of color compared with White patient cohorts?

How confident are you in your ability to assess AD in patients with skin of color?

How often do you consider healthcare disparities when developing treatment plans for patients with AD?

When determining the best treatment option for a patient, how frequently do you utilize shared decision-making?